Physician profile
Emanuel Martinez
NPI 1548264518
$4,189.63
in general payments reported to CMS, 2019-2025
24 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $117 · 2021: $554 · 2022: $739 · 2023: $1,100 · 2024: $493 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,385.21 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $405.51 | 2019-2022 | |
| Allergan, INC. | $383.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $244.65 | 2019-2023 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $240.36 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.79 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $166.32 | 2019-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $155.86 | 2019-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $120.73 | 2023-2024 | Quviviq |
| Livanova USA, INC. | $117.66 | 2021 | |
| Lundbeck LLC | $95.28 | 2021-2023 | Rexulti |
| Axsome Therapeutics, INC. | $90.19 | 2022-2023 | Auvelity |
| Alkermes, INC. | $78.09 | 2023-2024 | Aristada, Lybalvi |
| Corium, LLC | $68.84 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $66.58 | 2022-2024 | Hetlioz, Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $65.95 | 2019 | |
| Tris Pharma INC | $60.07 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $58.22 | 2022-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $56.22 | 2019-2023 | Ingrezza |
| Neos Therapeutics, LP | $35.35 | 2022 | |
| Almatica Pharma LLC | $25.26 | 2023 | Gralise |
| Jazz Pharmaceuticals INC. | $21.73 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.82 | 2019 | |
| Shire North American Group INC | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.